A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

Trial Details

NCT ID
NCT05607095
Phase
PHASE1
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Harrison, New York, United States|40.96899,-73.71263
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma.
  • o Patients will be eligible regardless of the number of prior systemic therapies received.
  • Cohort 2: Must have a confirmed diagnosis of unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma …
  • Unresectable disease will be defined by an expert sarcoma surgical oncologist as either (a) low likelihood of obtaining an R0 resection or (b) unac…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →